Mitochondria-targeted aggregation induced emission theranostics: crucial importance of in situ activation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shin, Weon Sup | - |
dc.contributor.author | Lee, Min-Goo | - |
dc.contributor.author | Verwilst, Peter | - |
dc.contributor.author | Lee, Joung Hae | - |
dc.contributor.author | Chi, Sung-Gil | - |
dc.contributor.author | Kim, Jong Seung | - |
dc.date.accessioned | 2021-09-04T05:02:01Z | - |
dc.date.available | 2021-09-04T05:02:01Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 2041-6520 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/90158 | - |
dc.description.abstract | Tissue selective targeting and specific suborganellular localization combined with an efficient pathology associated enzymatic activation of drugs in drug delivery systems may exhibit a clear advantage over conventional cancer treatment. Here, a mitochondria targeted aggregation induced emission (AIE) fluorophore further conjugated with an NAD(P)H: quinone oxidoreductase-1 (NQO1) cleavable masking unit showed preferential uptake in cancer cells and was selectively activated, resulting in bright AIE fluorescence and apoptosis via the caspase pathway, triggered by mitochondrial dysfunction. In vivo experimental data further support the conclusions from in vitro experiments, clearly showing the dependence of the therapy's success on both the suborganelle localization and specific in situ activation. And the site specific and enzyme dependent activation and aggregation was further supported by in vivo and ex vivo imaging. As a whole, the data comprised in this work represent a strong argument for the further development of this type of novel anticancer drugs. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ROYAL SOC CHEMISTRY | - |
dc.subject | MOLECULAR-ORBITAL METHODS | - |
dc.subject | DRUG-DELIVERY SYSTEM | - |
dc.subject | CANCER-THERAPY | - |
dc.subject | BASIS-SETS | - |
dc.subject | DENSITY | - |
dc.subject | DESIGN | - |
dc.subject | STRATEGIES | - |
dc.subject | AGENTS | - |
dc.subject | CELLS | - |
dc.subject | THERAPEUTICS | - |
dc.title | Mitochondria-targeted aggregation induced emission theranostics: crucial importance of in situ activation | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Min-Goo | - |
dc.contributor.affiliatedAuthor | Chi, Sung-Gil | - |
dc.contributor.affiliatedAuthor | Kim, Jong Seung | - |
dc.identifier.doi | 10.1039/c6sc02236g | - |
dc.identifier.scopusid | 2-s2.0-84983461986 | - |
dc.identifier.wosid | 000382488500054 | - |
dc.identifier.bibliographicCitation | CHEMICAL SCIENCE, v.7, no.9, pp.6050 - 6059 | - |
dc.relation.isPartOf | CHEMICAL SCIENCE | - |
dc.citation.title | CHEMICAL SCIENCE | - |
dc.citation.volume | 7 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 6050 | - |
dc.citation.endPage | 6059 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.subject.keywordPlus | MOLECULAR-ORBITAL METHODS | - |
dc.subject.keywordPlus | DRUG-DELIVERY SYSTEM | - |
dc.subject.keywordPlus | CANCER-THERAPY | - |
dc.subject.keywordPlus | BASIS-SETS | - |
dc.subject.keywordPlus | DENSITY | - |
dc.subject.keywordPlus | DESIGN | - |
dc.subject.keywordPlus | STRATEGIES | - |
dc.subject.keywordPlus | AGENTS | - |
dc.subject.keywordPlus | CELLS | - |
dc.subject.keywordPlus | THERAPEUTICS | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.